4//SEC Filing
Nolet Chris 4
Accession 0001479290-23-000062
CIK 0001479290other
Filed
May 4, 8:00 PM ET
Accepted
May 5, 5:14 PM ET
Size
7.5 KB
Accession
0001479290-23-000062
Insider Transaction Report
Form 4
Nolet Chris
Director
Transactions
- Award
Common Stock
2023-05-03+3,534→ 28,606 total - Award
Stock Option (Right to buy)
2023-05-03+5,915→ 5,915 totalExercise: $33.61Exp: 2033-05-02→ Common Stock (5,915 underlying)
Footnotes (2)
- [F1]Represents an annual restricted stock award (the "RSA") granted pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the earlier of (a) the one year anniversary, May 3, 2024 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to Mr. Nolet's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan (the "Plan")) through such vesting date.
- [F2]The shares subject to the stock option shall vest on the earlier of (a) the one year anniversary, May 3, 2024 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to Mr. Nolet's Continuous Service through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy.
Documents
Issuer
Revance Therapeutics, Inc.
CIK 0001479290
Entity typeother
Related Parties
1- filerCIK 0001782814
Filing Metadata
- Form type
- 4
- Filed
- May 4, 8:00 PM ET
- Accepted
- May 5, 5:14 PM ET
- Size
- 7.5 KB